E. Martínez

发表

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir‐boosted saquinavir. The CIVSA Study *

M. Arnedo, T. Pumarola, J. Mallolas, 2007, HIV medicine.

Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients *

Á. Soriano, J. Mallolas, M. Nomdedeu, 2007, HIV medicine.

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

J. Miro, J. Gatell, J. Mallolas, 2007, Revista clinica espanola.

Observational cohort study of rilpivirine (RPV) utilization in Europe

C. Leen, A. Mocroft, R. Paredes, 2022, AIDS Research and Therapy.

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *

J. Montaner, B. Clotet, E. Negredo, 2008, HIV medicine.

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

D. Podzamczer, E. Ribera, J. Macías, 2021, Open forum infectious diseases.

Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020

E. Fernández, J. Mallolas, J. Blanco, 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Á. Soriano, J. Mallolas, M. Laguno, 2022, Scientific Reports.

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

D. Podzamczer, J. Miro, D. Giralt, 2021, BMC Public Health.

Factors associated with the number of drugs in darunavir/cobicistat regimens.

E. Negredo, E. Ribera, M. Pérez-Elías, 2019, The Journal of antimicrobial chemotherapy.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

D. Podzamczer, B. Clotet, J. Romeu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).

J. M. García de Lomas, J. De La Torre, E. Ribera, 2019, The Journal of antimicrobial chemotherapy.

Once-daily antiretroviral therapy: Spanish Consensus Statement.

D. Podzamczer, J. Mallolas, J. Ena, 2005, The Journal of antimicrobial chemotherapy.

48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial

E. Negredo, A. Curran, F. Pulido, 2008 .

Increasing of New CA-MRSA Infections Detected in people living with HIV Who Engage in Chemsex in Barcelona: An Ambispective Study

Á. Soriano, J. Mallolas, J. Blanco, 2023, Infectious Diseases and Therapy.

Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.

J. Mallolas, J. Blanco, M. Laguno, 2023, The Journal of antimicrobial chemotherapy.

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

D. Podzamczer, J. Gatell, E. Martinez, 2007, AIDS.